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Background: Obesity is an important cardiovascular risk factor. This study tested the effect of obesity reduction on
preserving left ventricular ejection fraction (LVEF) and attenuating inflammation, oxidative stress and LV remodeling
in obese mice.
Methods and results: Eight-week-old C57BL/6 J mice (n=24) were equally divided into control (fed a control diet for
22 weeks), obesity (high-fat diet, 22 weeks), and obese reduction (OR) (high-fat diet, 14 weeks; then control diet,
8 weeks). Animals were sacrificed at post 22-week high-fat diet and the LV myocardium collected. Heart weight, body
weight, abdominal-fat weight, total cholesterol level and fasting blood glucose were higher in obesity than in control
and OR (all p<0.001). Inflammation measured by mRNA expressions of IL-6, MMP-9, PAI-1 and leptin and protein
expression of NF-κB was higher, whereas anti-inflammation measured by mRNA expressions of adiponectin and INF-γ
was lower in obesity than in control and OR (all p<0.003). Oxidative protein expressions of NOX-1, NOX-2 and oxidized
protein were higher, whereas expression of anti-oxidant markers HO-1 and NQO-1 were lower (all p<0.01); and
apoptosis measured by Bax and caspase 3 was higher, whereas anti-apoptotic Bcl-2 was lower in obesity as compared
with control and OR (all p<0.001). The expressions of fibrotic markers phosphorylated Smad3 and TGF-β were higher,
whereas expression of anti-fibrotic phosphorylated Smad1/5 and BMP-2 were lower (all p<0.02); and LVEF was lower,
whereas the LV remodeling was higher in obesity than in control and OR (all p<0.001).
Conclusion: Impaired LVEF, enhanced LV remodeling, inflammation, fibrosis, oxidative stress and apoptosis were
reversed by reduction in mouse obesity.
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Obesity is a major global problem that affects health and
quality of life [1-3]. Age-related increases in obesity are
associated with a notably higher prevalence of metabolic
disease, several common cancers, and numerous other
cardiovascular diseases [4-6]. Obesity has been also
shown to greatly increase functional limitations and* Correspondence: chyen0326@yahoo.com.tw; han.gung@msa.hinet.net
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reproduction in any medium, provided the ordisability [4-8]. Additionally, obesity adversely affects the
circulatory system resulting in endothelial dysfunction,
which promotes systemic hypertension, coronary artery
disease, and vascular calcification [9-12]. There is thus
an urgent need to develop comprehensive interventions
to mitigate obesity, especially in older adults.
Obesity is often characterized by increased local and
systemic oxidative stress and exacerbated inflammatory
reactions accompanied by infiltration of immune cells
into adipocytes[13-15]. Moreover, abundant data suggest
that oxidative stress and inflammatory signaling are not
only interrelated, but that their upregulation can lead totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tribute to atherosclerosis, cardiovascular diseases and
their associated features [5,13-19]. Previous study [20]
has revealed that oxidative stress and inflammation con-
tributed to the generation of cellular apoptosis and fi-
brosis in setting of dilated cardiomyopathy. The study
[20] has further identified that enhancement of these
biomarkers played an essential role on deteriorating the
heart function. However, whether these biomarkers are
also up-regulated in setting of obesity remains uncertain.
Although current scientific data emphasizes that obesity
is a risk factor for cardiovascular disease and highlights
the interplay between oxidative stress and inflammation
and obesity/diabetes onset [4-19], the relationship between
obesity and heart function is poorly understood. Some
clinical observation studies have demonstrated that LV
systolic and diastolic functions are impaired in patients
with metabolic syndrome even if they have normal LVEF
[21]. However, other studies have revealed that obesity isFigure 1 General appearance, illustration of M-mode echocardiograp
(n= 8 for each group). A) Comparison of general appearance of obesity m
period. B) to D) Showing both systolic (yellow arrows) and diastolic (white
normal control (B) that were revised by obesity reduction (D). E) to G) The
was noted among normal (E), obesity (F) and obesity reduction (G) animalonly associated with concentric LV remodeling without
change in ejection [22]. Pharmacologic and non-
pharmacologic interventions that target weight-loss bene-
fits are infrequently reported [23-25], especially with re-
spect to investigation of the benefit of obesity reduction
on LV function. Using a high fat diet-induced mouse
model of obesity, the aim of this study was to test the hy-
potheses that, in obese mice: 1) inflammation, oxidative
stress, fibrosis and apoptosis were significantly enhanced
in the LV myocardium; and 2) LV function was signifi-
cantly impaired, whereas LV remodeling was remarkably
increased in obese mice; and 3) molecular-cellular pertur-
bations, LV dysfunction and LV remodeling were signifi-
cantly reversed after reduction in obesity.
Materials and methods
Ethics
All animal experimental procedures were approved by
the Institute of Animal Care and Use Committee athy and pathological findings in among three groups of animals
ouse (yellow arrow) and normal B6 mouse (red arrow) at the study
arrows) dimensions were notably dilated in obesity mouse (C) than in
results of H & E stain showed no obstructive coronary artery disease
s.








IL-6 NM_012589.1 CCCTTCAGGAACAGCTATGAA 74
ACAACATCAGTCCCAAGAAGG
MMP-9 NM_031055.1 CCTCTGCATGAAGACGACATAA 64
GGTCAGGTTTAGAGCCACGA
Leptin NM_008493.3 CAGGATCAATGACATTTCACACA 145
GCTGGTGAGGACCTGTTGAT
IL-1β NM_214055.1 CCTGGACCTTGGTTCTCTGA 61
CCAGAGCTGGTGAGAGATTTG
Adiponectin NM_009605.4 GGAGAGAAAGGAGATGCAGGT 109
CTTTCCTGCCAGGGGTTC
PAI-1 NM_213910.1 GCCCTGGTGACTCATTTCA 65
CTCTCACGTGTCCACTGCTC
IFN-γ NM_008337.3 ATCTGGAGGAACTGGCAAAA 89
TTCAAGACTTCAAAGAGTCTGAGGTA
ET-1 M64711.1 TGTCTACTTCTGCCACCTGGA 69
CCTAGTCCATACGGGACGAC
AT-1R NM_030985.4 CACCCGATCACCGATCAC 110
CAGCCATTTTATACCAATCTCTCA
Bax NM_017059.1 GTGAGCGGCTGCTTGTCT 107
GACTCCAGCCACAAAGATGG
Caspase 3 NM_009810.2 TGAAGACATTTTGGAATTAATGGA 90
TCACCATGGCTTAGAATCACA
Bcl-2 NM_016993.1 GGGATGCCTTTGTGGAACT 82
CTGAGCAGCGTCTTCAGAGA
HO-1 NM_001004027 CATTCAGCTGTTTGAGGAGGT 64
CGAGGGTCTCTGGTCCTTAGT
NQO-1 NM_001159613 CCGAGAAGACGTCCTTCAAT 96
TGGCATACAGGTCCGACAC
α-actin DQ452569 CTGGACTTCGAGCAGGAGAT 69
GGCAGCTCGTAGCTCTTCAT
IL = interleukin; MMP = matrix metalloproteinase; PAI = lasminogen activator
inhibitor; IFN = interferon; ET = endothelin; AT-1R = angiotensin II type 1
receptor; HO = heme oxygenase; NQO = NAD(P)H quinone oxidoreductase.
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formed in accordance with the Guide for the Care and
Use of Laboratory Animals (NIH publication No. 85–23,
National Academy Press, Washington, DC, USA, 1996).
Animal model of obesity
Eight-week-old male C57BL/6 J mice (n = 24), weighing
22–24 g, (Charles River Technology, BioLASCO, Tai-
wan), were fed with a high-fat diet (45 kcal% fat; Re-
search Diets) to create a diet-induced obesity model.
According to the literature [26] and the instructions
from the diet manufacturer, successful obesity induction
is defined as an increase in mouse body weight of more
than 35 % after feeding with the diet for 13 weeks. After
feeding with the high fat diet for 12 weeks, 75 % mice in
our study fit the criteria of obesity (Figure 1-A).
Sixteen of the obese mice were then equally divided
into two groups: obesity that were continuously fed with
a high fat diet for further 10 weeks, and obese reduction
(i.e., body-weight reduction) that were continuously fed
with a high fat diet for further 2 weeks, followed by
standard mouse chow (i.e., the control diet) for a subse-
quent 8 weeks. Another group (normal control) of age-
matched C57BL/6 J mice (n = 8) were fed with for the
same duration (22-weeks) with a control diet that was
also purchased from the same company (Research
Diets). This group served as untreated controls.
Functional assessment by echocardiography
All animals underwent transthoracic echocardiography
under anesthesia in a supine position at the beginning and
end of the study. The procedure was performed by an ani-
mal cardiologist blind to the experimental design using a
VisualSonics ultrasound machine (Vevo, 2100). M-mode
standard two-dimensional (2DE) left parasternal-long axis
echocardiographic examination was conducted. Left ven-
tricular internal dimensions [end-systolic diameter (ESD)
and end-diastolic diameter (EDD)] were measured accord-
ing to the American Society of Echocardiography leading-
edge method using at least three consecutive cardiac
cycles (Figure 1-B, 1-C, 1-D). LVEF was calculated as fol-
lows: LVEF (%)=[(LVEDD3-LVEDS3)/LVEDD3] × 100
Real-time quantitative PCR analysis
Real-time reverse transcription polymerase chain reaction
(RT-qPCR) was conducted using LighCycler TaqMan
Master (Roche, Germany) in a single capillary tube
according to the manufacturer’s guidelines for individual
component concentrations. Forward and reverse primers
(Table 1) were each designed in a different exon of the tar-
get gene sequence, eliminating the possibility of amplifying
genomic DNA. The negative control (single primer test
and templateless) was also performed for each assay.Total RNA was extracted using a spin column-based
RNA extraction kit (RNeasy Fibrous Tissue Mini Kit,
Qiagen) according to protocols provided by manufac-
turer. Reverse transcriptions were performed with the
Transcriptor First Strand cDNA Synthesis Kit (Roche).
Briefly, 1 μg of total RNA was mixed with 50 pmole
oligo dT and then incubated at 65 °C for 10 minutes.
After incubation on ice for 5 minutes, 4 μL of 5× reverse
transcriptase reaction buffer, 0.5 μL of RNase inhibitor
(40 U/μl), 2 μL of dNTP (10 mM for each), and 0.5 μL
of reverse transcriptase (20 U/μL) were added into tubes
containing hybridized RNA-oligo dT mixtures. RT
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were performed on a Light Cycler (Roche Molecular
Biochemicals). Each reaction was carried out with 1 μL
of cDNA, 5 μL of 2× reaction mixtures (Maxima Probe
qPCR Master Mix), 0.15 μL or each primer (20 μM), 0.2
μL of probe, and 3.5 μL of sterile distilled water. Reac-
tions were performed by incubating at 95 °C for 10 min-
utes, following with 45 cycles of 95 °C for 10 sec, 60 °C
for 30 sec, and 72 °C for 1 sec. Analysis of melting
curves and determination of threshold cycle (Ct) were
performed by the Light Cycler instrument software pro-
vided by Roche.
Isolation of mitochondria from LV myocardium
The procedure and protocol of mitochondrial isolation
were described in details in our previous report [20].
Briefly, the LV myocardium was excised and washed
with buffer A (100 mM Tris–HCl, 70 mM sucrose,
10 mM EDTA, and 210 mM mannitol, pH 7.4). Samples
were minced finely in cold buffer A and incubated for
10 minutes at 4 °C. All samples were homogenized in an
additional 3 mL of buffer A using a motor-drivenTable 2 The Baseline Characteristics, Laboratory Findings and
Variables Control
(n=8)
Initial body weight (g) 26.0 ± 0.72
Final body weight (g) 34.4 ± 1.48a
Heart weight (g) 0.14 ± 0.01a
Ratio of heart weight to tibial bone length 0.070± 0.001a
Abdominal fat weight (g) 1.66 ± 0.41a
Total cholesterol (mg/dl)† 136.3 ± 11.8a
Initial fasting blood glucose level (mg/dl)† 98.3 ± 9.0
Final fasting blood glucose level (mg/dl)† 142.5 ± 18.3a
Echocardiograph (baseline)
Thickness of inter-ventricular septum (mm) 0.83 ± 0.09
Thickness of posterior wall (mm) 0.76 ± 0.09
Left ventricular end-diastolic dimension (mm) 3.93 ± 0.26
Left ventricular end-systolic dimension (mm) 2.63 ± 0.23
Fractional shortening (%) 34.4 ± 2.01
Left ventricular ejection fraction (%) 64.0 ± 2.49
Echocardiograph (at end of study period)
Thickness of inter-ventricular septum (mm) 0.86 ± 0.08
Thickness of posterior wall (mm) 0.77 ± 0.03
Left ventricular end-diastolic dimension (mm) 4.18 ± 0.16a
Left ventricular end-systolic dimension (mm) 2.78 ± 0.13a
Fractional shortening (%) 33.44 ± 0.85a
Left ventricular ejection fraction (%) 62.66 ± 1.43a
* performed by ANOVA; means with different letters (a, b, c) indicate significant diff
† value was observed after 12 fasting in the mice.grinder. The homogenate was centrifuged twice at 700 g
for 10 minutes at 4 °C. The supernatant was centrifuged
again at 8,500 g for 15 minutes, and the pellets were
washed with buffer B (10 mM Tris–HCl, 70 mM su-
crose, 1 mM EDTA, and 230 mM mannitol, pH 7.4).
The mitochondria-rich pellets were collected and stored
at −70 °C.
Western blot analysis
The procedure and protocol of protein extracts from LV
myocardium were described in details in our previous
report [20]. Briefly, equal amounts (10–30 μg) of protein
extracts from LV myocardium of the animals were
loaded and separated by SDS-PAGE using 12 % acryl-
amide gradients. The membranes were incubated with
monoclonal antibodies against phospho-Smad 3 (1:1000,
Cell Signaling), transforming growth factor (TGF)-β
(1:500, Abcam), phospho-Smad1/5 (1:1000, Cell Signal-
ing), bone morphogenic protein (BMP)-2 (1:500,
Abcam), NADPH oxidase (NOX)-1 (1: 1000, Abcam),
NOX-2 (1: 1000, Abcam), NAD(P)H Quinone Oxidore-
ductase (NQO 1) (1: 1000, Abcam), Heme OxygenaseEchocardiography Results
Obesity Obese reduction P value*
(n=8) (n =8)
25.7 ± 0.66 25.7 ± 0.87 0.675
43.9 ± 1.55b 35.4 ± 2.21a <0.0001
0.19 ± 0.02b 0.15 ± 0.02a <0.0001
0.095± 0.002b 0.075± 0.017a <0.001
4.09 ± 0.65b 2.35 ± 0.08c <0.0001
232.8 ± 7.53b 188.8 ± 9.45c <0.001
103± 8.6 101.3 ± 9.4 0.688
307.5 ± 74.7b 181.2 ± 19.7c <0.0001
0.82 ± 0.08 0.818± 0.098 0.616
0.77 ± 0.11 0.776± 0.089 0.720
4.10 ± 0.10 4.108± 0.083 0.117
2.71 ± 0.21 2.69 ± 0.170 0.809
32.7 ± 1.98 32.98 ± 1.64 0.240
62.5 ± 2.43 62.27 ± 2.04 0.455
0.87 ± 0.06 0.859± 0.07 0.789
0.79 ± 0.08 0.791± 0.09 0.916
4.456± 0.17b 4.22 ± 0.19a 0.016
3.462± 0.49b 3.09 ± 0.33c <0.001
22.82 ± 1.15b 27.86 ± 1.61c <0.001
46.04 ± 1.95b 54.05 ± 5.41c <0.001
erence (at level 0.05) by Bonferroni’s multiple-comparisons post hoc test.
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250, Abcam), Bax (1: 1000, Abcam), caspase 3 (1:1000,
Cell Signaling) and Bcl-2 (1: 200, Abcam). Signals were
detected with HRP-conjugated goat anti- mouse or goat
anti-rabbit IgG.
Oxyblot protein analysis was carried out using Oxyblot
Oxidized Protein Detection Kit from Chemicon (S7150).
Proteins were transferred to nitrocellulose membranes
which were then incubated in the primary antibodyFigure 2 Inflammatory and anti-inflammatory biomarkers in left vent
group). A) to E) The mRNA expressions of interleukin (IL)-1β, IL-6, matrix m
leptin, indices of inflammation, were significantly higher in obesity group t
were significantly higher in obese-reduction group than in control group. *
adiponectin and interferon (INF)-γ, two indicators of anti-inflammatory and
group than in control and obese-reduction groups, and significantly lower
H) The nuclear factor (NF)-κB protein expression was significantly higher in
showed no difference in the later two groups. * vs. †, p<0.01. All statistical
comparison post hoc test. Symbols (*, †, {) indicate significance (at 0.05 levsolution (anti-DNP 1: 150) for two hours, followed by incu-
bation with second antibody solution (1:300) for one hour
at room temperature. The washing procedure was repeated
eight times within 40 minutes. Immunoreactive bands were
visualized by enhanced chemiluminescence (ECL; Amer-
sham Biosciences) which was then exposed to Biomax L
film (Kodak). For quantification, ECL signals were digitized
using Labwork software (UVP). For oxyblot protein ana-
lysis, a standard control was loaded on each gel.ricular myocardium at the end of study period (n= 8 for each
etalloproteinase (MMP)-9, plasminogen activator inhibitor (PAI)-1 and
han in control and obese-reduction groups, and except for IL-1β, other
vs. † vs. {, or * vs. †, p<0.001. F) and G) The mRNA expressions of
immunomodulatory biomarkers, were significantly lower in obesity
in obese-reduction group than in control group. * vs. † vs. {, p<0.001.
obesity group than in control and obese-reduction groups, but it
analyses using one-way ANOVA, followed by Bonferroni multiple
el) among A) to H).
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Quantitative data are expressed as means ± SD. Statis-
tical analysis was adequately performed by ANOVA fol-
lowed by Bonferroni’s multiple-comparisons post hoc
test. Statistical analysis was performed using SAS statis-
tical software for Windows version 8.2 (SAS institute,
Cary, NC). A P value of less than 0.05 was considered
statistically significant.
Results
Baseline characteristics, laboratory and echocardiography
data, and histology of left ventricle (n=8 for each group)
Data were summarized in Table 2. Initial body weight and
fasting blood sugar did not differ among the normal con-
trols (control), the obese mice (obesity) and the obesity in-
duction followed by subsequent body weight reduction
group (obese reduction). However, the final body weight
was substantially higher in the obesity than in control andFigure 3 The mRNA and protein expressions of vasoconstriction and
mRNA expressions of endothelin (ET)-1 and angiotensin II type I receptor (A
microcirculation, were remarkably increased in obesity group than in contr
reduction group than in control group. * vs. † vs. {, p<0.001. C) Showing t
shown on left lower panel represent control oxidized molecular protein sta
dinitrophenylhydrazone. a = normal, b = obesity, c = obese reduction. D) Sh
group than in normal and obese-reduction groups, and significantly highe
p<0.001. All statistical analyses using one-way ANOVA, followed by Bonferr
significance (at 0.05 level) among A), B), and D).obese reduction (p<0.0001). There was no difference in
body weight between control and obese reduction. Final
fasting blood sugar, abdominal fat weight and serum chol-
esterol were considerably higher in obesity than in control
and obese reduction, and significantly higher in obese re-
duction than in control (all p <0.001). Total heart weight
and ratio of heart weight to tibial bone length were con-
siderably higher in obesity than in control and obese re-
duction (p<0.001), but there was no significant difference
between the later two groups.
The transthoracic echocardiographic findings showed
that the thickness of interventricular septum and posterior
wall prior to and at the end of the study period were simi-
lar among all the groups of animals. Additionally, before
induction of obesity, the LVEDD, LVESD, LVEF and the
LV fractional shortening (%) showed no difference among
the three groups. However, by the end of study period, the
LVEDD and LVESD were significantly higher in obesityoxidative-stress markers (n = 8 for each group). A) and B) The
T-1R), two indicators of vasoconstrictions/impairment of
ol and obese-reduction groups, and notably increased in obese-
he Western blot of oxidized protein (Note: Right lane and left lane
ndard and protein molecular weight marker, respectively). DNP= 1–3
owing significantly higher oxidative index, protein carbonyls, in obesity
r in obese-reduction group than in control group. * vs. † vs. {,
oni multiple comparison post hoc test. Symbols (*, †, {) indicate
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notably higher in obese reduction than in control (all
p<0.02), whereas the LVEDD did not differ between these
two groups. Conversely, LVEF and the LV fractional short-
ening were significantly lower in obesity than the control
and obese reduction, and significantly lower in obese re-
duction than in the control (all p<0.001).
The histological findings (i.e., H&E staining) of LV
myocardium revealed no atherosclerotic obstructive cor-
onary artery disease among three groups of the animals.
Protein and mRNA expressions of inflammatory and anti-
inflammatory biomarkers in the LV myocardium at the
End of the study period (n=8 for each group)
To determine the effect of obesity and obesity reduction
on inflammatory reaction in the LV Myocardium, RT-PCR
and western blot were performed (Figure 2). The results
showed that mRNA expressions of interleukin (IL)-1β, IL-
6, matrix metalloproteinase (MMP)-9, plasminogen activa-
tor inhibitor (PAI-1) and leptin, five indices of inflamma-
tion, were significantly higher in the obesity than in control
and obese reduction, and all of these parameters except for
IL-1β were significantly higher in obese reduction than in
the control (all p <0.001). Additionally, the proteinFigure 4 The mRNA and protein expressions of reactive oxygen spec
gene (A, B) and protein (C, D) expressions of NADPH oxidase (NOX)-1 and
obesity group than in normal and obese-reduction groups, and notably hig
† vs. {, p<0.001; For C & D). * vs. † vs. {, p<0.01. All statistical analyses usin
hoc test. Symbols (*, †, {) indicate significance (at 0.05 level) among A) toexpression of NF-κB, also an index of inflammation was
significantly higher in obesity than in control and obese re-
duction (p<0.01), but it showed no difference in obese re-
duction as compared with the control. On the other hand,
the mRNA expressions of adiponectin, an anti-
inflammatory biomarker, and interferon (INF)-γ, an immu-
nomodulatory biomarker, were remarkably lower in obesity
than in control and obese reduction, and significantly
lower in obese reduction than in control (all p<0.001).
Protein and mRNA expressions of markers of
vasoconstriction and oxidative stress in LV myocardium
at the End of study period (n=8 for each group)
To elucidate the effects of obesity and reduction in obesity
on vasoconstriction and oxidative stress, RT-PCR and
western blot were performed (Figures 3 and 4). The mRNA
expression of endothelin (ET)-1, an indicator of endothelial
dysfunction, was markedly increased in the obesity in com-
parison with control and obese reduction, and was also sig-
nificantly increased in obese reduction in comparison with
control (Figure 3) (p<0.001). The mRNA expression of
angiotensin II type I receptor (AT-1R) (Figure 3), an indica-
tor of vasoconstriction and reactive oxygen species (ROS),
showed the same pattern as ET-1 among the three groupsies (ROS) (n = 8 for each group). A & B) and C & D) showing the
NOX-2, two indexes of ROS generation, were remarkably higher in
her in obese-reduction group than in normal group. For A & B) * vs.
g one-way ANOVA, followed by Bonferroni multiple comparison post
D).
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of oxyblot (i.e., protein carbonyls) (Figure 3), an index of
oxidation, and mRNA and protein expressions of NOX-1
and NOX-2 (Figure 4), two indices of ROS, were signifi-
cantly increased in obesity in comparison with control and
obese reduction, and notably increased in obese reduction
in comparison with control (all p<0.01).
Protein and mRNA and expressions of apoptotic and anti-
apoptotic biomarkers in LV myocardium at the End of
study period (n=8 for each group)
To investigate the potential impact of obesity and
obesity reduction on apoptosis, apoptotic and anti-Figure 5 Apoptic and anti-apoptotic biomarkers (n = 8 for each group
significantly higher in obesity group than in control and obese-reduction g
control group. * vs. † vs. {, p<0.001. C) The Bax protein expression in mito
obese-reduction groups, but it displayed no difference between the later t
expression was significantly higher in obesity group than in control and ob
group than in control group. * vs. † vs. {, p<0.005. E) & F) showing the m
obesity group than in control and obese-reduction groups, and protein ex
control group. * vs. † vs. {, or * vs. †, p<0.008. All statistical analyses using
hoc test. Symbols (*, †, {) indicate significance (at 0.05 level) among A) toapoptotic biomarkers were detected by RT-PCR and
western blotting (Figure 5). Protein and mRNA
expressions of Bax (mitochondrial) and caspase 3
(cleaved caspase 3 protein expression), two apoptotic
biomarkers, were remarkably higher in obesity than in
control and obese reduction, and the caspase 3 was
notably higher in obese reduction than in control (all
p<0.01), but Bax showed no difference between these
two groups. Conversely, the mRNA and protein
expressions of Bcl-2, an anti-apoptotic biomarker,
were significantly lower in obesity than in control and
obese reduction, and notably lower (only in protein
level) in obese reduction than in control (p<0.008).). A) & B) The mRNA expressions of Bax and caspase 3 were
roups, and significantly higher in obese-reduction group than in
chondria was notably higher in obesity group than in control and
wo groups. * vs. †, p<0.006. D) The cleaved caspase 3 protein
ese-reduction groups, and significantly higher in obese-reduction
RNA E) and protein (F) expressions of Bcl-2 were significantly lower in
pression of Bcl-2 significantly lower in obese-reduction group than in
one-way ANOVA, followed by Bonferroni multiple comparison post
F).
Wang et al. Journal of Translational Medicine 2012, 10:145 Page 9 of 13
http://www.translational-medicine.com/content/10/1/145Protein expressions of fibrotic and anti-fibrotic
biomarkers in LV myocardium at the End of study period
(n=8 for each group)
To understand the influence of obesity and reduction in
obesity on the protein expressions of fibrotic and anti-
fibrotic markers in the LV myocardium, western blot
analysis was performed (Figure 6). As expected, the pro-
tein expressions of TGF-β and phosphorylated Smad3,
two indices of fibrosis, were significantly higher in obes-
ity than in control and obese reduction, and significantly
higher in obese reduction than in control (all p<0.005).
In contrast to these findings, the protein expressions of
BMP-2 and phosphorylated Smad1/5, two anti-fibrotic
indicators, showed an opposite pattern to TGF-β and
phosphorylated Smad3 in the three groups (p<0.001).
Protein and mRNA expressions of anti-oxidant biomarkers
in the LV myocardium at the End of study period (n=8 for
each group)
To examine whether reduction in obesity could restore the
anti-oxidant effect in the LV myocardium, anti-oxidantFigure 6 The fibrotic and anti-fibrotic biomarkers (n = 8 for each grou
β and phosphorylated Smad3, two indicators of fibrosis, were significantly hig
notably higher in obese-reduction group than in control group. * vs. † vs. {, p
(BMP)-2 and phosphorylated Smad1/5, two indices of anti-fibrosis, were rema
significantly lower in obese-reduction group than in control group. * vs. † vs.
Bonferroni multiple comparison post hoc test. Symbols (*, †, {) indicate signifibiomarkers were detected by RT-PCR and western blot
(Figure 7). The results demonstrated that the mRNA and
protein expressions of HO-1 and NQO-1, two indices of
anti-oxidant cell response, were remarkably higher in obese
reduction than in control and obesity, and significantly
higher in obesity than in control (all p<0.0001).
Discussion
This study investigated the role of obesity and subsequent
reduction in obesity on heart function using a mouse model
of obesity. Inflammation, oxidative stress, ROS, vasocon-
striction, apoptosis and fibrosis in the LV myocardium were
all attenuated by reduction in obesity. Further, obesity-
impaired anti-oxidant expression and LV function were
restored by reduction in obesity, and obesity-promoted LV
remodeling was inhibited by reduction in obesity.
Benefit of obesity reduction preserving heart function
and inhibiting LV remodeling
The most important finding in this study was that com-
pared with normal controls, LVEF and LV fractionalp). A) & B) The protein expressions of transforming growth factor (TGF)-
her in obesity group than in control and obese-reduction groups, and
<0.005. C) & D) The protein expressions of bone morphogenic protein
rkably lower in obesity than in control and obese-reduction groups, and
{, p<0.001. All statistical analyses using one-way ANOVA, followed by
cance (at 0.05 level) among A) to D).
Figure 7 The mRNA and protein expressions of anti-oxidant biomarkers (n = 8 for each group). The mRNA (A, B) and protein (C, D)
expressions of heme oxygenase (HO)-1 and NAD(P)H Quinone Oxidoreductase (NQO) 1 were significantly higher in obese-reduction group than
in control and obesity groups, and significantly higher in obesity group than in control group. * vs. † vs. {, p<0.0001. All statistical analyses using
one-way ANOVA, followed by Bonferroni multiple comparison post hoc test. Symbols (*, †, {) indicate significance (at 0.05 level) among A) to D).
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LVESD, two indexes of LV remodeling, were notably
higher in obese animals. Of particular importance, LV
function was significantly preserved and LV remodeling
was remarkably attenuated in animals following obesity/
body-weight reduction.
It is well known that hyperglycemia and obesity are
the two components of metabolic syndrome. Addition-
ally, metabolic syndrome which is frequently found to be
associated with the presence of dyslipidemia and insulin
resistance that are the risk factors of atherosclerosis. The
obese mice in the current study also exhibited the ma-
jority of these atherosclerotic risk factors. A previous
study showed that poor DM control impaired LVEF [27].
However, the results of our study did not support the
finding of poor DM control that ultimately impaired the
LVEF function. Additionally, although echocardiography
revealed that LV function was impaired in obese mice,
the pathological findings (i.e., H.&.E stain) did not find
any obstructive coronary artery disease. This finding
suggests that other confounders rather than atheroscler-
otic obstructive coronary artery disease could play a cru-
cial role in impairing heart function obese mice. Our
suggestion may be supported by the fact that previousreports have stated that nearly 20% of DM patients are
diagnosed with diabetic cardiomyopathy because of
myocardial dysfunction and congestive heart failure
(CHF) in the absence of coronary artery disease [28,29].
However, the mechanistic basis of myocardial dysfunc-
tion remains uncertain in setting of obesity.
Impact of reduction in obesity in attenuating
inflammation, oxidative stress and generation of
vasoconstriction and ROS
Undoubtedly, increased oxidative stress, ROS and in-
flammatory processes which involve the endothelium
and smooth muscle are essential in the development of
all stages of atherosclerosis [14,18,19,30-33]. In addition,
the association between obesity, inflammation and oxi-
dative stress [13-15,34] and cardiovascular disease [9-
13,15,16] is well documented. However, whether chronic
inflammation and oxidative stress also take place in the
LV myocardium is currently unclear, particularly, the oc-
currence is related to obesity-induced increases in oxida-
tive stress and inflammation are unknown. One
important finding of the present study was that as com-
pared with normal controls, the ROS (gene and protein
expressions of NOX-1 and NOX-2), inflammatory
Wang et al. Journal of Translational Medicine 2012, 10:145 Page 11 of 13
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MMP-9, PAI-1 and leptin) and oxidative (oxidized pro-
tein) biomarkers in the LV myocardium were found to
be substantially increased in obese mice. Additionally,
vasoconstriction was increased and levels of ROS were
higher in obese mice than in normal controls. In a previ-
ous study we found that inflammatory reactions
enhanced the levels of ET-1 and generation of oxidative
stress in the myocardium [35]. Our current findings,
support the findings of this previous study [35], and fur-
ther suggest interplay among inflammation, oxidative
stress, generation of ROS and ET-1 in the obese myocar-
dium. Importantly, these biomarkers were remarkably
decreased following reduction in obesity. Enhanced in-
flammatory reaction and oxidative stress are associated
with myocardial damage and deterioration of heart func-
tion [27,35]. Our findings could at least partially explain
why LV function was impaired in obese mice and
restored in obese mice after weight reduction.Role of reduction in obesity in ameliorating apoptosis
and fibrosis and preserving anti-oxidant functions
As compared with normal controls, the apoptotic biomar-
kers (protein expressions of Bax and casapse 3) in LV
myocardium were significantly enhanced in obese mice.
On the other hand, the anti-apoptotic biomarker (protein
expression of Bcl-2) in the LV myocardium was markedly
suppressed in obese mice. Furthermore, an association be-
tween increased apoptotic and fibrotic biomarkers (pro-
tein expressions of TGF-β and p-Samd3) in the LV
myocardium in obese mice was also found. Of importance,Figure 8 Proposed molecular-cellular factors underlying the effects o
a mouse model based on the findings of the present study. AT-1 = an
endothelin; HO = mheme oxygenase, IL-1 = interleukin 1, INF-γ = interfero
NOX = NADPH oxidase; NQO = NAD(P)H Quinone Oxidoreductase; PAI = p
p-Smad3 = phosphorylated Smad3; TGF-β = transforming growth factor bethese parameters were notably decreased whereas the
anti-fibrotic biomarkers (the protein expressions of BMP-
2 and p-Smad1/5) were significantly increased in mice
after reduction in obesity. In a rodent model of dilated car-
diomyopathy, myocardial apoptosis and fibrosis were
markedly enhanced in the myocardium in association with
remarkably reduced LV function [20]. Our current find-
ings compare with those findings [20], and may also partly
explain why LVEF was significantly reduced and LV re-
modeling was markedly increased in obese animals.
HO-1 and NQO1 are markedly deceased in acute lung
and kidney ischemia-reperfusion injury [36,37]. These
two anti-oxidant biomarkers, whose expression was
reversed after stem-cell therapy, are known to play an
important role for against the renal parenchyma from
ischemia-reperfusion injury [36,37]. A principal finding
in the present study was that the gene and protein
expressions of anti-oxidant biomarkers (i.e., HO-1 and
NQO 1) in LV myocardium were significantly sup-
pressed in obese mice and reversed in obese animals
after body weight reduction. Hence, our findings, in
addition to reinforcing the findings of those experimen-
tal studies [36,37], may also partially explain why mar-
kers of apoptosis and fibrosis and LV remodeling were
significantly increased whereas LV function was notably
reduced in obese mice, and these indicators were ame-
liorated after reduction in obesity.Study limitations
This study has several limitations. First, this study did
not address whether inflammation and oxidative stressf obesity control (i.e., body weight reduction) on heart function in
giotensin II type 1; BMP-2 = bone morphogenic protein 2; ET =
n-gamma; MMP-9 = matrix metalloproteinase; NF-κB=nuclear factor-κB;
lasminogen activator inhibitor; p-Smad1/5 = phosphorylated Smad1/5;
ta.
Wang et al. Journal of Translational Medicine 2012, 10:145 Page 12 of 13
http://www.translational-medicine.com/content/10/1/145was the cause of apoptosis and fibrosis in the LV myo-
cardium of obese mice or vice versa. Second, another
control group of weight-reduced with a high-fat diet did
not performed in the current study. Thus, we did not
completely exclude the possibility of confounding factor
of diet composition that influenced the results of the
present study. Third, we remain uncertain for why anti-
oxidant markers were higher in obesity than control,
and were highest in obese reduction. Perhaps, these
findings suggest that inherent anti-oxidant system can
be initiated by obesity in the LV myocardium in re-
sponse to obesity-induced stress and that this effect can
be further enhanced by reduction in obesity. The protein
expressions of leptin and adiponectin receptors and the
serum levels of these two biomarkers which would pro-
vide a more complete understanding on the mechanistic
basis of obesity-related signaling pathway for LV dys-
function were not examined in the current study. Finally,
although LV remodeling was significantly increased and
LVEF was decreased in obese animals in comparison to
animals in which obesity was reduced, we remain uncer-
tain whether these ROS, inflammatory and oxidative-
stress biomarkers directly participated in affecting the
heart function. Overproduction of circulating aldoster-
one in setting of obesity has been reported by previous
studies [38]. An increase in circulating level of this
neuropeptide hormone, an indicator of renin-
angiotensin-aldosterone system (RAAS), is undoubtedly
harmful to the cardiovascular system. This perhaps
could also patriotically explain the findings of our study.
The molecular-cellular factors we propose to be involved
in the observed changes are illustrated in Figure 8.Conclusion
This study demonstrated that in a mouse model, obesity
enhanced inflammation, oxidative stress, apoptosis, fibro-
sis and LV remodeling, and impaired LV function; and all
these traits could be reversed by a reduction in obesity.
Our findings highlight the important role of obesity in
damage to the myocardium, and show that such damage
may be caused by factors other than those related to
atherosclerotic-obstructive coronary artery disease.Competing interests
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